Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Partially aligned with the label for indication and formulation/route, but includes multiple unsupported mechanistic claims and multiple specific efficacy/side-effect/on-treatment-duration claims that are not supported by the provided prescribing information; also includes a treatment-duration claim that is directly contradicted by the label.
Category Scores
Accurate Statements
Efinaconazole is prescribed for topical treatment of onychomycosis.
Supported by label Indications and Usage (topical treatment of onychomycosis of the toenail[s]).
Efinaconazole is prescribed for topical treatment of toenail onychomycosis in adults.
Supported by label Indications and Usage and that clinical studies assessed subjects 18 years and older.
Efinaconazole is an azole antifungal.
Supported by label: “is an azole antifungal.”
Efinaconazole is typically available in a solution form.
Supported by label Dosage Forms and Strengths (topical solution, 10%).
Unsupported Statements
Efinaconazole inhibits the enzyme lanosterol 14α-demethylase.
Mechanism claim not present in provided label sections.
Efinaconazole inhibits ergosterol synthesis in fungi.
Mechanism claim not present in provided label sections.
Ergosterol is a key component of the fungal cell membrane.
General mechanistic/biological assertion not present in provided label sections.
By disrupting ergosterol production, efinaconazole compromises the integrity of the fungal cell membrane.
Mechanism claim not present in provided label sections.
Compromising the integrity of the fungal cell membrane leads to fungal cell death.
Mechanism claim not present in provided label sections.
Efinaconazole is available for purchase from online retailers such as Amazon.
Label does not discuss retail/online purchase channels.
Efinaconazole is a prescription medication.
Label sections provided do not state prescription status.
Efinaconazole requires a prescription from a healthcare professional.
Label sections provided do not state prescription requirement.
Clinical studies have shown improvement in nail appearance after 24 weeks of efinaconazole treatment.
Provided label efficacy description does not mention nail-appearance improvement at 24 weeks.
Clinical studies have shown fungal clearance after 24 weeks of efinaconazole treatment.
Provided label efficacy description provides endpoints assessed at Week 52 (4 weeks after completion), not 24-week fungal clearance.
The most common side effects of efinaconazole include ingrown toenails.
Adverse reactions section content is not provided in the supplied label text, and this specific claim is not supported by the shown sections.
The most common side effects of efinaconazole include redness at the application site.
Redness is mentioned in counseling as possible persistent irritation, but the claim that it is among the 'most common side effects' is not supported by the provided label sections.
The most common side effects of efinaconazole include blistering.
Adverse reactions details are not provided in the supplied label text supporting blistering as 'most common.'
Efinaconazole cannot be purchased over-the-counter.
Label sections provided do not address OTC vs prescription availability.
Efinaconazole requires a valid prescription from a licensed healthcare professional.
Label sections provided do not state this requirement.
Contradictions
High
AI Statement
Treatment with efinaconazole for onychomycosis typically lasts for 24 weeks.
Label Reference
Dosage and Administration: apply once daily for 48 weeks. Clinical Studies: trials compared 48 weeks of treatment; efficacy assessed at Week 52.
Important Omissions
Label-accurate treatment duration and key application details (once daily for 48 weeks; complete coverage of toenail/tail structures using integrated flow-through brush; for topical use only).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A direct contradiction of the indicated treatment duration (24 weeks claimed vs 48 weeks labeled) and unsupported claims about adverse effects and efficacy timing may lead to inaccurate patient expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Treatment duration at 24 weeks directly contradicts label instructions for 48 weeks.
Suggested Improvement
Replace the 24-week duration and any 24-week efficacy assertions with label-consistent dosing duration (48 weeks) and label-consistent efficacy assessment timing (Week 52, 4 weeks after completion). Remove or qualify unsupported mechanistic, side-effect, and purchase/prescription-status claims not present in the provided label sections.